Compare Dover Corp (DOV) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs 22nd Century Group Inc — how do they compare? Dover Corp trades at $188.84 (market cap $25.45B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Dover Corp is far larger — about 40938.1× 22nd Century Group Inc's market cap, and Dover Corp pays a 1.11% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and 22nd Century Group Inc for 32 Days on average.
| DOV | XXII | |
|---|---|---|
Market Cap | $25.45B | $621.67K |
Volume | 661,758 | 45,625 |
Sector | Industrials | Consumer Staples |
52-Week High | $233.31 | $483.00 |
52-Week Low | $161.16 | $0.80 |
Typical Hold Time | 73 Days | 32 Days |
Enterprise Value | $26.95B | -$3.69M |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOV trades at $189.32, up 0.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q3 2026 results pending. Revenue for 2025 was $8.09B, with a net income margin of 13.48%, while analyst consensus is strongly positive with a $243.20 price target. Recent news highlights product launches and strategic acquisitions, such as the completion of the Cloeren acquisition in August 2026.
DOV presents a favorable fundamental outlook with solid profitability and analyst support, though technical indicators suggest near-term caution. Upside potential exists from earnings momentum and dividend reliability, but risks include market volatility and execution challenges from recent acquisitions. The stock's current price is below the consensus target, indicating room for growth if quarterly results meet expectations.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
